CY1122565T1 - Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης - Google Patents

Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης

Info

Publication number
CY1122565T1
CY1122565T1 CY20191101170T CY191101170T CY1122565T1 CY 1122565 T1 CY1122565 T1 CY 1122565T1 CY 20191101170 T CY20191101170 T CY 20191101170T CY 191101170 T CY191101170 T CY 191101170T CY 1122565 T1 CY1122565 T1 CY 1122565T1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
oxymetazoline
surgical treatment
eyelash
Prior art date
Application number
CY20191101170T
Other languages
English (en)
Inventor
Mark M. D. SILVERBERG
Original Assignee
Voom, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voom, Llc filed Critical Voom, Llc
Publication of CY1122565T1 publication Critical patent/CY1122565T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Παρέχονται φαρμακευτικές συνθέσεις και μέθοδοι χρήσης των συνθέσεων για τη μη χειρουργική θεραπεία της βλεφαρόπτωσης (πτώση βλεφάρων). Σε μία εφαρμογή, η σύνθεση περιλαμβάνει 0,1% οξυμεταζολίνη, μορφοποιημένη φαρμακοτεχνικά για τοπική χρήση στο μάτι. Σε μία εφαρμογή, η σύνθεση περιλαμβάνει συνεργικό συνδυασμό οξυμεταζολίνης και φαινυλεφρίνης, μορφοποιημένη φαρμακοτεχνικά για τοπική χρήση στο μάτι. Η οξυμεταζολίνη μόνη της δεν προκαλεί διαστολή της κόρης (μυδρίαση) και ο συνεργικός συνδυασμός οξυμεταζολίνης και φαινυλεφρίνης δεν επάγει κλινικά σημαντική μυδρίαση. Εκτός της επίτευξης επιθυμητού αισθητικού αποτελέσματος, οι συνθέσεις και οι μέθοδοι της εφεύρεσης μπορούν να βελτιώσουν τα οπτικά πεδία, τα οποία τίθενται σε κίνδυνο λόγω της βλεφαρόπτωσης.
CY20191101170T 2011-03-03 2019-11-07 Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης CY1122565T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161448949P 2011-03-03 2011-03-03
US13/218,584 US20120225918A1 (en) 2011-03-03 2011-08-26 Compositions and Methods for Non-Surgical Treatment of Ptosis
US13/270,577 US8357714B2 (en) 2011-03-03 2011-10-11 Compositions and methods for non-surgical treatment of ptosis
PCT/US2012/026496 WO2012118704A1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis

Publications (1)

Publication Number Publication Date
CY1122565T1 true CY1122565T1 (el) 2021-01-27

Family

ID=46753678

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101170T CY1122565T1 (el) 2011-03-03 2019-11-07 Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης

Country Status (23)

Country Link
US (8) US20120225918A1 (el)
EP (2) EP2680829B1 (el)
JP (1) JP6106100B2 (el)
KR (1) KR101889392B1 (el)
CN (1) CN103501771B (el)
AU (1) AU2012223615B2 (el)
BR (1) BR112013022094A2 (el)
CA (1) CA2827285C (el)
CY (1) CY1122565T1 (el)
DK (1) DK2680829T3 (el)
ES (1) ES2750123T3 (el)
HR (1) HRP20192266T1 (el)
HU (1) HUE046740T2 (el)
LT (1) LT2680829T (el)
MX (1) MX345042B (el)
PL (1) PL2680829T3 (el)
PT (1) PT2680829T (el)
RS (1) RS59636B1 (el)
RU (1) RU2582392C2 (el)
SG (1) SG192801A1 (el)
SI (1) SI2680829T1 (el)
WO (1) WO2012118704A1 (el)
ZA (1) ZA201307262B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
AU2012311239B2 (en) 2011-09-20 2017-10-19 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US20140329874A1 (en) * 2013-05-06 2014-11-06 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
CA2869060A1 (en) * 2014-07-28 2016-01-28 Queen's University At Kingston Dosage forms and methods for diagnosing sympathetic nervous system dysfunction
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
AU2017211793B2 (en) * 2016-01-26 2022-11-24 Levation Pharma Ltd. Compositions and uses of alpha-adrenergic agents
CN106726115B (zh) * 2016-12-22 2023-01-20 上海交通大学医学院附属第九人民医院 一种眼睑功能矫正器
CN106938039A (zh) * 2017-03-29 2017-07-11 卢仁华 眼睑下垂的治疗药物
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN108635434A (zh) * 2018-06-24 2018-10-12 吴安相 一种治疗眼睑下垂的侗族中药配方
WO2020109957A1 (en) * 2018-11-26 2020-06-04 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
EP4138882A4 (en) * 2020-04-23 2024-04-10 Okogen Inc TREATMENT OF VIRAL CONJUNCTIVITIS
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1117588B (de) 1960-09-30 1961-11-23 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates
US3670087A (en) * 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3227741A1 (de) 1982-07-24 1984-01-26 Hoechst Ag, 6230 Frankfurt 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung
FR2549015B1 (fr) * 1983-07-13 1986-06-13 Oreal Ensemble compte-gouttes
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
AU7081598A (en) * 1997-04-24 1998-11-13 Taisho Pharmaceutical Co., Ltd. Eye drops
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
JP2004509920A (ja) * 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
US7780976B2 (en) * 2002-05-30 2010-08-24 Eye Care And Cure, Asia Apparatus and method for delivering controlled quantities of one or more agents to the eye
AR039703A1 (es) * 2002-06-20 2005-03-09 Novartis Consumer Health Sa Composiciones nasales
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7022740B2 (en) 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP4942328B2 (ja) * 2004-11-01 2012-05-30 ロート製薬株式会社 ビタミンｂ６類含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4956981B2 (ja) * 2005-01-05 2012-06-20 大正製薬株式会社 オキシメタゾリン含有水性組成物
JP5275214B2 (ja) 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
JP2009535342A (ja) * 2006-04-26 2009-10-01 アーシエックス， インコーポレイテッド 眼瞼腫脹の予防および処置のための組成物
US8466203B2 (en) 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
CN101977595A (zh) * 2007-11-08 2011-02-16 阿西克斯医疗公司 用于治疗以及预防眼睑肿胀的组合物
ES2910374T3 (es) * 2009-03-17 2022-05-12 Nicox Ophthalmics Inc Formulaciones oftálmicas de cetirizina y procedimientos de uso
EP2437602A4 (en) 2009-06-05 2014-02-19 Aciex Therapeutics Inc OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
KR20130128375A (ko) 2010-08-06 2013-11-26 갈데르마 리서치 & 디벨로프먼트 피부 질환을 치료 또는 예방하기 위한 화합물들의 배합물
ES2618907T3 (es) 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
RU2648439C2 (ru) * 2011-02-15 2018-03-26 Аллерган, Инк. Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2013177594A2 (en) 2012-05-25 2013-11-28 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
AU2017211793B2 (en) 2016-01-26 2022-11-24 Levation Pharma Ltd. Compositions and uses of alpha-adrenergic agents
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders

Also Published As

Publication number Publication date
ZA201307262B (en) 2015-02-25
CN103501771A (zh) 2014-01-08
KR20140013013A (ko) 2014-02-04
MX345042B (es) 2017-01-16
US20160038465A1 (en) 2016-02-11
PL2680829T3 (pl) 2020-03-31
PT2680829T (pt) 2019-12-10
WO2012118704A1 (en) 2012-09-07
US10912765B2 (en) 2021-02-09
CA2827285C (en) 2019-05-07
HRP20192266T1 (hr) 2020-03-20
NZ614719A (en) 2015-05-29
BR112013022094A2 (pt) 2017-06-27
US8357714B2 (en) 2013-01-22
RS59636B1 (sr) 2020-01-31
EP2680829B1 (en) 2019-09-25
US20120225918A1 (en) 2012-09-06
RU2582392C2 (ru) 2016-04-27
EP2680829A1 (en) 2014-01-08
JP6106100B2 (ja) 2017-03-29
US20200009114A1 (en) 2020-01-09
AU2012223615A1 (en) 2013-10-24
EP3653205A2 (en) 2020-05-20
US9867808B2 (en) 2018-01-16
MX2013009597A (es) 2014-01-08
EP3653205A3 (en) 2020-08-26
US20220218669A1 (en) 2022-07-14
AU2012223615B2 (en) 2017-03-02
KR101889392B1 (ko) 2018-08-17
CN103501771B (zh) 2016-05-11
US20120225919A1 (en) 2012-09-06
JP2014506927A (ja) 2014-03-20
US20120225920A1 (en) 2012-09-06
DK2680829T3 (da) 2019-11-18
SG192801A1 (en) 2013-09-30
SI2680829T1 (sl) 2020-02-28
HUE046740T2 (hu) 2020-03-30
US20180338953A1 (en) 2018-11-29
US9018240B2 (en) 2015-04-28
CA2827285A1 (en) 2012-09-07
ES2750123T3 (es) 2020-03-25
RU2013142602A (ru) 2015-04-10
US20200360345A1 (en) 2020-11-19
LT2680829T (lt) 2019-12-27

Similar Documents

Publication Publication Date Title
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1119163T1 (el) Αμιδια πυριδονης ως ρυθμιστες διαυλων νατριου
CY1126109T1 (el) Αναστολεις toy trpc6
IN2014DN09434A (el)
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX2015008187A (es) Inhibidores de alk deuterados.